{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:21:14Z","timestamp":1740122474100,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs has partially surpassed this issue. However, in the setting of concomitant atrial fibrillation (AF) and PCI clopidogrel is still the most adopted P2Y<jats:sub>12<\/jats:sub> inhibitor. In the present study all consecutive patients with history of AF discharged from our cardiology ward with dual (DAT) or triple (TAT) antithrombotic therapy after a PCI from April 2018 to March 2021 were enrolled in an observational registry. For all subjects, blood serum samples were collected and tested for platelet reactivity by arachidonic acid and ADP (VerifyNow system) and genotyping of the CYP2C19*2 loss-of-function polymorphism. We recorded at 3 and 12-months follow-up: (1) major adverse cardiac and cerebrovascular events (MACCE), (2) major hemorrhagic or clinically relevant non-major bleeding and (3) all-cause mortality. A total of 147 patients were included (91, 62% on TAT). In 93.4% of patients, clopidogrel was chosen as P2Y<jats:sub>12<\/jats:sub> inhibitor. P2Y<jats:sub>12<\/jats:sub> dependent HPR resulted an independent predictor of MACCE both at 3 and 12\u00a0months (HR 2.93, 95% C.I. 1.03 to 7.56, p\u2009=\u20090.027 and HR 1.67, 95% C.I. 1.20 to 2.34, p\u2009=\u20090.003, respectively). At 3-months follow-up the presence of CYP2C19*2 polymorphism was independently associated with MACCE (HR 5.21, 95% C.I. 1.03 to 26.28, p\u2009=\u20090.045). In conclusion, in a real-world unselected population on TAT or DAT, the entity of platelet inhibition on P2Y<jats:sub>12<\/jats:sub> inhibitor is a potent predictor of thrombotic risk, suggesting the clinical utility of this laboratory evaluation for a tailored antithrombotic therapy in this high-risk clinical scenario.\n<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>\n                <jats:p>The present analysis was performed in patients with AF undergoing PCI on dual or triple antithrombotic therapy. At 1\u00a0year follow-up MACCE incidence was consistent, and it was not different in different antithrombotic pattern groups. P2Y<jats:sub>12<\/jats:sub> dependent HPR was a potent independent predictor of MACCE both at 3- and 12-months follow-up. In the first 3 months after stenting the carriage of CYP2C19*2 allele was similarly associated with MACCE. Abbreviation: DAT, dual antithrombotic therapy; HPR, high platelet reactivity; MACCE, major adverse cardiac and cerebrovascular events; PRU, P2Y<jats:sub>12<\/jats:sub> reactive unit; TAT, triple antithrombotic therapy. Created with BioRender.com.<\/jats:p>","DOI":"10.1007\/s11239-023-02784-z","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T15:53:13Z","timestamp":1678895593000},"page":"667-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8281-4734","authenticated-orcid":false,"given":"M.","family":"Berteotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fortini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ciardetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"2784_CR1","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","volume":"43","author":"R De Caterina","year":"2022","unstructured":"De Caterina R, Agewall S, Andreotti F et al (2022) Great Debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J 43:3512\u20133527. https:\/\/doi.org\/10.1093\/eurheartj\/ehac294","journal-title":"Eur Heart J"},{"key":"2784_CR2","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, Stent Anticoagulation Restenosis Study Investigators et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339:1665\u20131671. https:\/\/doi.org\/10.1056\/NEJM199812033392303","journal-title":"N Engl J Med"},{"key":"2784_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jcin.2017.03.028","volume":"10","author":"D Capodanno","year":"2017","unstructured":"Capodanno D, Angiolillo DJ (2017) Triple antithrombotic therapy at the intercept between threats and opportunities: don\u2019t throw out the baby with the bath water. JACC Cardiovasc Interv 10:1086\u20131088. https:\/\/doi.org\/10.1016\/j.jcin.2017.03.028","journal-title":"JACC Cardiovasc Interv"},{"key":"2784_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903\u20131912. https:\/\/doi.org\/10.1016\/S0140-6736(06)68845-4","journal-title":"Lancet"},{"key":"2784_CR5","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","volume":"121","author":"JS Paikin","year":"2010","unstructured":"Paikin JS, Wright DS, Crowther MA et al (2010) Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 121:2067\u20132070","journal-title":"Circulation"},{"key":"2784_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2018.09.001","volume":"73","author":"Y Saito","year":"2019","unstructured":"Saito Y, Kobayashi Y (2019) Triple therapy: a review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention. J Cardiol 73:1\u20136. https:\/\/doi.org\/10.1016\/j.jjcc.2018.09.001","journal-title":"J Cardiol"},{"key":"2784_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R S\u00f8rensen","year":"2009","unstructured":"S\u00f8rensen R, Hansen ML, Abildstrom SZ et al (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374:1967\u20131974. https:\/\/doi.org\/10.1016\/S0140-6736(09)61751-7","journal-title":"Lancet"},{"key":"2784_CR8","doi-asserted-by":"publisher","first-page":"ehw325","DOI":"10.1093\/eurheartj\/ehw525","volume":"38","author":"M Valgimigli","year":"2016","unstructured":"Valgimigli M, Costa F, Lokhnygina Y et al (2016) Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 38:ehw325. https:\/\/doi.org\/10.1093\/eurheartj\/ehw525","journal-title":"Eur Heart J"},{"key":"2784_CR9","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423\u20132434. https:\/\/doi.org\/10.1056\/NEJMoa1611594","journal-title":"N Engl J Med"},{"key":"2784_CR10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513\u20131524. https:\/\/doi.org\/10.1056\/NEJMoa1708454","journal-title":"N Engl J Med"},{"key":"2784_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509\u20131524. https:\/\/doi.org\/10.1056\/NEJMoa1817083","journal-title":"N Engl J Med"},{"key":"2784_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet 394:1335\u20131343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0","journal-title":"The Lancet"},{"key":"2784_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz732","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Goette A, Tijssen J et al (2019) Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomiz. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz732","journal-title":"Eur Heart J"},{"key":"2784_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"2784_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ et al (2021) 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77:629\u2013658. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.011","journal-title":"J Am Coll Cardiol"},{"key":"2784_CR16","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000001406","author":"R Marcucci","year":"2022","unstructured":"Marcucci R, Berteotti M, Gragnano F et al (2022) Monitoring antiplatelet therapy: where are we now? J Cardiovasc Med. https:\/\/doi.org\/10.2459\/JCM.0000000000001406","journal-title":"J Cardiovasc Med"},{"key":"2784_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1160\/TH09-06-0418","volume":"103","author":"F Sofi","year":"2010","unstructured":"Sofi F, Marcucci R, Gori AM et al (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103:841\u2013848. https:\/\/doi.org\/10.1160\/TH09-06-0418","journal-title":"Thromb Haemost"},{"key":"2784_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1160\/TH10-01-0007","volume":"104","author":"R Marcucci","year":"2010","unstructured":"Marcucci R, Gori AM, Paniccia R et al (2010) High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 104:279\u2013286. https:\/\/doi.org\/10.1160\/TH10-01-0007","journal-title":"Thromb Haemost"},{"key":"2784_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.thromres.2010.10.021","volume":"127","author":"SJ Hwang","year":"2011","unstructured":"Hwang SJ, Jeong YH, Kim IS et al (2011) The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 127:23\u201328. https:\/\/doi.org\/10.1016\/j.thromres.2010.10.021","journal-title":"Thromb Res"},{"key":"2784_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","volume":"14","author":"M Galli","year":"2021","unstructured":"Galli M, Franchi F, Rollini F et al (2021) Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol 14:963\u2013978","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2784_CR21","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762\u20131771. https:\/\/doi.org\/10.1093\/eurheartj\/ehv104","journal-title":"Eur Heart J"},{"key":"2784_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamaneurol.2013.601","volume":"70","author":"ASY Zheng","year":"2013","unstructured":"Zheng ASY, Churilov L, Colley RE et al (2013) Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol 70:208\u2013213. https:\/\/doi.org\/10.1001\/jamaneurol.2013.601","journal-title":"JAMA Neurol"},{"key":"2784_CR23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126","journal-title":"J Thromb Haemost"},{"key":"2784_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 39:119\u2013177. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"2784_CR25","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","volume":"44","author":"RL Sacco","year":"2013","unstructured":"Sacco RL, Kasner SE, Broderick JP et al (2013) An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association\/American stroke association. Stroke 44:2064\u20132089. https:\/\/doi.org\/10.1161\/STR.0b013e318296aeca","journal-title":"Stroke"},{"key":"2784_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005657","author":"G Patti","year":"2017","unstructured":"Patti G, Lucerna M, Pecen L et al (2017) Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.005657","journal-title":"J Am Heart Assoc"},{"key":"2784_CR27","doi-asserted-by":"publisher","first-page":"e010956","DOI":"10.1161\/JAHA.118.010956","volume":"8","author":"G Crimi","year":"2019","unstructured":"Crimi G, Morici N, Ferrario M et al (2019) Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc 8:e010956. https:\/\/doi.org\/10.1161\/JAHA.118.010956","journal-title":"J Am Heart Assoc"},{"key":"2784_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040449","author":"G Palareti","year":"2020","unstructured":"Palareti G, Antonucci E, Legnani C et al (2020) Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2020-040449","journal-title":"BMJ Open"},{"key":"2784_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11239-019-01923-9","volume":"49","author":"V Russo","year":"2020","unstructured":"Russo V, Attena E, di Maio M et al (2020) Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis 49:42\u201353. https:\/\/doi.org\/10.1007\/s11239-019-01923-9","journal-title":"J Thromb Thrombolysis"},{"key":"2784_CR30","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/a-1731-3922","volume":"122","author":"L Bertoletti","year":"2022","unstructured":"Bertoletti L, Gusto G, Khachatryan A et al (2022) Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a nationwide comparative cohort study in France. Thromb Haemost 122:1384\u20131396. https:\/\/doi.org\/10.1055\/a-1731-3922","journal-title":"Thromb Haemost"},{"key":"2784_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s00380-022-02027-w","volume":"37","author":"T Sakai","year":"2022","unstructured":"Sakai T, Motoki H, Fuchida A et al (2022) Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists. Heart Vessels 37:1232\u20131241. https:\/\/doi.org\/10.1007\/s00380-022-02027-w","journal-title":"Heart Vessels"},{"key":"2784_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","volume":"8","author":"C Combescure","year":"2010","unstructured":"Combescure C, Fontana P, Mallouk N et al (2010) Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 8:923\u2013933. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03809.x","journal-title":"J Thromb Haemost"},{"key":"2784_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","volume":"160","author":"D Aradi","year":"2010","unstructured":"Aradi D, Kom\u00f3csi A, Vorobcsuk A et al (2010) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160:543\u2013551. https:\/\/doi.org\/10.1016\/j.ahj.2010.06.004","journal-title":"Am Heart J"},{"key":"2784_CR34","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/nejmoa1209979","volume":"367","author":"J-P Collet","year":"2012","unstructured":"Collet J-P, Cuisset T, Rang\u00e9 G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100\u20132109. https:\/\/doi.org\/10.1056\/nejmoa1209979","journal-title":"N Engl J Med"},{"key":"2784_CR35","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla G, Cuisset T, Silvain J et al (2016) Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388:2015\u20132022. https:\/\/doi.org\/10.1016\/S0140-6736(16)31323-X","journal-title":"Lancet"},{"key":"2784_CR36","doi-asserted-by":"publisher","first-page":"e002129","DOI":"10.1136\/openhrt-2022-002129","volume":"9","author":"A Aluvilu","year":"2022","unstructured":"Aluvilu A, Ferro A (2022) Role of platelet function testing in acute coronary syndromes: a meta-analysis. Open Heart 9:e002129. https:\/\/doi.org\/10.1136\/openhrt-2022-002129","journal-title":"Open Heart"},{"key":"2784_CR37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","volume":"397","author":"M Galli","year":"2021","unstructured":"Galli M, Benenati S, Capodanno D et al (2021) Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 397:1470\u20131483. https:\/\/doi.org\/10.1016\/S0140-6736(21)00533-X","journal-title":"Lancet"},{"key":"2784_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081565","author":"J Gruttemeier","year":"2021","unstructured":"Gruttemeier J, Cottin Y, Yao H et al (2021) Impact of platelet reactivity in acs patients on clinical outcomes with triple antithrombotic therapy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10081565","journal-title":"J Clin Med"},{"key":"2784_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-022-02723-4","author":"I Lianos","year":"2022","unstructured":"Lianos I, Varlamos C, Benetou D-R et al (2022) Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-022-02723-4","journal-title":"J Thromb Thrombolysis"},{"key":"2784_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jama.2011.1332","volume":"306","author":"G Parodi","year":"2011","unstructured":"Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215. https:\/\/doi.org\/10.1001\/jama.2011.1332","journal-title":"JAMA"},{"key":"2784_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11239-014-1159-1","volume":"40","author":"R Valenti","year":"2015","unstructured":"Valenti R, Marcucci R, Capodanno D et al (2015) Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. J Thromb Thrombolysis 40:76\u201382. https:\/\/doi.org\/10.1007\/s11239-014-1159-1","journal-title":"J Thromb Thrombolysis"},{"key":"2784_CR42","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O\u2019Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908\u20132913. https:\/\/doi.org\/10.1161\/01.CIR.0000072771.11429.83","journal-title":"Circulation"},{"key":"2784_CR43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","volume":"52","author":"AM Gori","year":"2008","unstructured":"Gori AM, Marcucci R, Migliorini A et al (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52:734\u2013739. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.032","journal-title":"J Am Coll Cardiol"},{"key":"2784_CR44","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367","journal-title":"Eur Heart J"},{"key":"2784_CR45","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 304:1821\u20131830. https:\/\/doi.org\/10.1001\/jama.2010.1543","journal-title":"JAMA"},{"key":"2784_CR46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3109\/09537104.2012.658106","volume":"23","author":"R Marcucci","year":"2012","unstructured":"Marcucci R, Giusti B, Paniccia R et al (2012) High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 23:586\u2013593. https:\/\/doi.org\/10.3109\/09537104.2012.658106","journal-title":"Platelets"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02784-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02784-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:59:11Z","timestamp":1682740751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02784-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02784-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"5 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carlo di Mario: institutional research grants from AMGEN, Abbott Vascular, Behring, Boston Scientific, Chiesi Pharmaceuticals, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Shockwave Medical, and Philips Volcano. Niccol\u00f2 Marchionni: lecture for Daichi- Sankyo, BMS, Bayer. Research grants from BMS. Rossella Marcucci: lecture fees from Sanofi; AMGEN; Bayer; Viatris; Werfen; Pfizer; Daichi- Sankyo. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}